AUTHOR=Yang Libang , Yang Jianbo , Jacobson Blake , Gilbertsen Adam , Smith Karen , Higgins LeeAnn , Guerrero Candace , Xia Hong , Henke Craig A. , Lin Jizhen 

TITLE=SFPQ Promotes Lung Cancer Malignancy via Regulation of CD44 v6 Expression

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.862250

DOI=10.3389/fonc.2022.862250

ISSN=2234-943X

ABSTRACT=<p>Mesenchymal stem cells (MSCs) contribute to tumor pathogenesis and elicit antitumor immune responses in tumor microenvironments. Nuclear proteins might be the main players in these processes. In the current study, combining spatial proteomics with ingenuity pathway analysis (IPA) in lung non-small cell (NSC) cancer MSCs, we identify a key nuclear protein regulator, SFPQ (Splicing Factor Proline and Glutamine Rich), which is overexpressed in lung cancer MSCs and functions to promote MSCs proliferation, chemical resistance, and invasion. Mechanistically, the knockdown of SFPQ reduces CD44v6 expression to inhibit lung cancer MSCs stemness, proliferation <italic>in vitro</italic>, and metastasis <italic>in vivo</italic>. The data indicates that SFPQ may be a potential therapeutic target for limiting growth, chemotherapy resistance, and metastasis of lung cancer.</p>